By Cambrian Bio –
Cambrian Bio, a clinical-stage drug development company whose pipeline platforms include therapeutics targeting critical metabolic pathways that decline with age, today announced that it has been awarded funding to support the development of its next-generation selective mTORC1 inhibitors from the PROactive Solutions for Prolonging Resilience (PROSPR) program within the Advanced Research Projects Agency for Health (ARPA-H).
Cambrian’s TORnado platform has created a series of highly selective mTORC1 inhibitors designed to preserve the widely validated healthspan benefits of mTOR inhibition, while explicitly avoiding the side-effect liabilities associated with mTORC2 inhibition, resulting in a more favorable benefit-risk profile for preventative use.
